Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Mar Kristjansson Clear advanced filters

  • The concentration of SARS-CoV-2 changes during an individual’s infection, and mutations accumulate as viruses are transmitted between people. Here, the authors use data from Iceland to demonstrate how this information can be exploited at the population-level to determine the phase of the epidemic.

    • Hakon Jonsson
    • Olafur T. Magnusson
    • Kari Stefansson
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-8

  • Iceland has used four different SARS-CoV-2 vaccines in various combinations. Here, the authors describe differences in the immune responses elicited by different initial/booster vaccine combinations, and then use population-level data to assess the effects of booster doses against Delta and Omicron infection.

    • Gudmundur L. Norddahl
    • Pall Melsted
    • Kari Stefansson
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-10

  • Ingileif Jonsdottir, Kari Stefansson and colleagues show that variants in the HLA class II region contribute to tuberculosis risk in populations of European ancestry. They propose that the associated variants influence disease risk by altering expression of HLA class II molecules presenting protective M. tuberculosis antigens to T cells.

    • Gardar Sveinbjornsson
    • Daniel F Gudbjartsson
    • Kari Stefansson
    Research
    Nature Genetics
    Volume: 48, P: 318-322

  • Holm, Ivarsdottir, Olafsdottir et al. compare symptoms and physical measures between Icelanders post SARS-CoV-2 infection with uninfected controls. From reported symptoms, they estimate the prevalence of long COVID as 7% at a median of 8 months after infection, while objective differences between cases and controls in the physical measures were few.

    • Hilma Holm
    • Erna V. Ivarsdottir
    • Kari Stefansson
    ResearchOpen Access
    Communications Medicine
    Volume: 3, P: 1-13